TRAVERE THERAPEUTICS, INC. Accounts Payable
TRAVERE THERAPEUTICS, INC. (TVTX) had Accounts Payable of $7.50 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-04
- 2026-06-30: Accounts Payable, Current $7.50M.
- 2026-03-31: Accounts Payable, Current $12.91M.
- 2025-12-31: Accounts Payable, Current $24.80M.
- 2025-09-30: Accounts Payable, Current $18.23M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.50M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $12.91M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $24.80M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $18.23M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $19.13M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $15.37M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $23.53M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $23.20M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $25.84M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $16.73M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $41.67M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $24.74M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $19.91M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $16.73M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $17.29M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $14.01M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $11.85M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $18.43M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $15.14M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $5.83M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $8.34M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $15.01M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $12.13M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $9.43M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $10.20M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $9.97M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $26.61M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $13.83M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $12.52M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $7.63M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $6.95M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $9.31M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $7.85M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $9.42M 10-Q · filed 2018-07-06 | |
| 2017-12-31 | $18.94M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $7.37M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $9.08M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $4.67M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $7.52M 10-K · filed 2018-07-06 | |
| 2016-09-30 | $3.07M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $6.29M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $4.65M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $7.64M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $4.89M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $4.78M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $5.91M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $7.12M 10-K · filed 2016-02-26 | $7.12M 10-K · filed 2015-03-11 |
| 2014-09-30 | $11.29M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $10.63M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $5.71M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $3.55M 10-K/A · filed 2015-07-09 | |
| 2013-09-30 | $1.72M 10-Q/A · filed 2015-07-09 | |
| 2013-06-30 | $1.43M 10-Q · filed 2013-09-16 | |
| 2013-03-31 | $484.72K 10-Q/A · filed 2013-09-16 | |
| 2012-12-31 | $1.02M 10-Q/A · filed 2015-07-09 | |
| 2011-12-31 | $340.13K 10-K/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |